Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse-Transcriptase Inhibitors in HIV Type 1–Infected Children

Tim R. Cressey,1,2 Hannah Green,3 Saye Khoo,4 Jean-Marc Treluyer,5 Alexandra Compagnucci,6 Yacine Saidi,6 Marc Lallemant,1,2 Diana M. Gibb,3 and David M. Burger,7 for the Paediatric European Network for Treatment of AIDS II Study Group*

1Institut de Recherche pour le Développement, Program for HIV Prevention and Treatment, UR 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; 2Harvard School of Public Health, Harvard University, Boston, Massachusetts; 3MRC Clinical Trials Unit, London, and 4University of Liverpool, Liverpool, United Kingdom; 5Hôpital Saint Vincent de Paul and 6INSERM SC10, Paris, France; and 7Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Background. The optimum strategy for stopping treatment with drugs that have different half-lives in a combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated drug concentrations in plasma, human immunodeficiency virus (HIV) load, and development of drug resistance after a planned treatment interruption of a nonnucleoside reverse-transcriptase inhibitor (NNRTI)–containing regimen in HIV type 1–infected children.

Methods. Children with viral loads <50 copies/mL and CD4 cell percentages ≥30% (for children aged 2–6 years) or CD4 cell percentages ≥25% and CD4 cell counts ≥500 cells/μL (for children aged 7–15 years) were randomized to either a planned treatment interruption or to continuous therapy. In the planned treatment interruption arm, either (1) treatment with nevirapine or efavirenz was stopped, and treatment with the remaining drugs was continued for 7–14 days, or (2) nevirapine or efavirenz were replaced by a protease inhibitor, and all drugs were stopped after 7–14 days. Sampling for determination of plasma drug concentrations, measurement of viral load, and drug resistance testing was scheduled at day 0, day 7 (drug concentrations only), day 14, and day 28 after interruption of treatment with an NNRTI.

Results. Treatment with an NNRTI was interrupted for 35 children (20 were receiving nevirapine, and 15 were receiving efavirenz). Median time from NNRTI cessation to stopping all drugs was 9 days (range, 6–15 days) for nevirapine and 14 days (range, 6–18 days) for efavirenz. At 7 days, 1 (5%) of 19 and 4 (50%) of 8 children had detectable nevirapine and efavirenz concentrations, respectively; efavirenz remained detectable in 3 (25%) of 12 children at 14 days. At 14 days, viral load was ≥50 copies/mL in 6 of 16 children interrupting treatment with nevirapine (range, 52–7000 copies/mL) and in 2 of 12 children interrupting treatment with efavirenz (range, 120–1600 copies/mL). No new NNRTI mutations were observed.

Conclusions. In children with virological suppression who experienced interruption of treatment with an NNRTI, staggered or replacement stopping strategies for a median of 9 days for nevirapine and 14 days for efavirenz were not associated with the selection of NNRTI resistance mutations.

Current antiretroviral treatment guidelines recommend continuous HAART for the treatment of HIV infection and AIDS; however, whether planned or unplanned, therapy is sometimes interrupted. Triple-combination HAART regimens typically contain drugs with different half-lives; therefore, stopping a HAART regimen may lead to temporary functional monotherapy and, as viral load rebounds, can potentially increase the risk of selecting drug-resistant viruses [1].

Among the antiretroviral drug classes, nonnucleoside
reverse transcriptase inhibitors (NNRTIs) have the longest plasma half-lives; 25–30 h for nevirapine [2] and 40–55 h for efavirenz [3]. The majority of nucleoside reverse-transcriptase inhibitors (NRTIs) and protease inhibitors have plasma half-lives of <10 h. Thus, the risk of temporary functional monotherapy when simultaneously stopping all drugs in an NNRTI-containing regimen is high, and because NNRTIs have a low genetic barrier to within-class drug resistance, this situation could potentially compromise the efficacy of future NNRTI-containing regimens. Other drugs with low genetic barriers, such as the NRTI lamivudine, may also be susceptible to the development of resistance in this situation, especially because its active moiety, the intracellular drug triphosphate, has a half-life of ~20 h [2].

In adults, several studies have examined the persistence of NNRTI plasma drug concentrations after treatment interruption. Efavirenz plasma concentrations can persist for >14 days after stopping therapy [3]. In contrast, at steady state, nevirapine plasma concentrations did not persist >14 days after treatment interruption [4], although after a single dose of nevirapine during labor for the prevention of mother-to-child transmission of HIV, plasma concentrations have been detected up to 21 days postpartum [5].

The impact of selecting NNRTI-resistant strains after treatment interruption on subsequent NNRTI-based therapy has been highlighted in the prevention of mother-to-child transmission of HIV setting. HIV-infected women exposed to single-dose nevirapine during labor were found to be less likely to achieve virologic suppression after 6 months of postpartum treatment with an NNRTI-based regimen, compared with nonexposed women [6]. Short-course, dual-NRTI treatment postpartum (administered for 3–7 days) after administration of single-dose nevirapine has been shown to reduce the risk of selecting NNRTI-resistant strains [7], but the optimal choice and duration of such treatment remains unknown.

To date, no pediatric data after NNRTI treatment interruption are available. Therefore, in the context of a pediatric phase II exploratory planned treatment interruption (PTI) trial, we describe plasma drug concentrations, viral rebound, and selection of HIV drug resistance mutations in children receiving an NNRTI-based HAART regimen during the first PTI cycle in the trial.

PATIENTS, MATERIALS, AND METHODS

Study population. All children were enrolled in the Paediatric European Network for Treatment of AIDS (PENTA) 11: Treatment Interruption in Children with Chronic HIV-Infection Trial. PENTA-11 is an ongoing, open, randomized, phase II exploratory trial evaluating the role of PTIs in the treatment of HIV-infected children who have responded well to antiretroviral therapy (ISRCTN36694210; http://www.controlled-trials.com). Children receiving stable HAART for at least 6 months with plasma HIV-1 RNA levels <50 copies/mL and a CD4 cell percentage ≥30% (for children aged 2–6 years) or a CD4 cell percentage ≥25% and CD4 cell count ≥500 cells/μL (for children aged 7–15 years) were randomized 1:1 to either continue antiretroviral therapy or undergo a CD4 cell–guided PTI and were followed up for at least 72 weeks. This study was approved by the ethics committees of all participating sites.

Children randomized to the PTI strategy and taking a regimen that included an NNRTI and/or lamivudine stopped therapy with either a staggered stop or a replacement stop strategy, at the discretion of the pediatrician. The original protocol (23 June 2005) recommended that, for a staggered stop strategy, treatment with the NNRTI should be stopped at randomization, and treatment with the remaining 2 drugs should be continued for 7 days. For a replacement stop strategy, the NNRTI should be switched to a single or ritonavir-boosted protease inhibitor and treatment with the 3 drugs should be continued for 7 days. For either strategy, if the regimen contained lamivudine, there was an option to switch lamivudine to an alternative NRTI with a high genetic barrier to resistance and a short half-life prior to continuing the dual-NRTI regimen. In February 2006, an interim analysis showed that all 10 children who stopped treatment with nevirapine had plasma concentrations <0.15 mg/L at day 7, but at least 2 children had detectable concentrations with use of a more sensitive assay (0.06 and 0.064 mg/L). Three of 7 children who stopped efavirenz had detectable efavirenz plasma concentrations at day 14. Therefore, the protocol was amended (on 10 March 2006) to recommend a staggered stop or replacement stop for 7–14 days for nevirapine and for at least 14 days for efavirenz. Here, we present data for all children in the PENTA-11 trial who stopped treatment with nevirapine had plasma concentrations <0.02 mg/L at day 7, but at least 2 children had detectable concentrations with use of a more sensitive assay (0.06 and 0.064 mg/L). Three of 7 children who stopped efavirenz had detectable efavirenz plasma concentrations at day 14. Therefore, the protocol was amended (on 10 March 2006) to recommend a staggered stop or replacement stop for 7–14 days for nevirapine and for at least 14 days for efavirenz. Here, we present data for all children in the PENTA-11 trial who stopped treatment with nevirapine- or efavirenz-containing regimens during their first PTI. NNRTI plasma drug concentrations and HIV-1 RNA load were measured at 0, 7 (drug concentrations only), 14, and 28 days after stopping treatment with the NNRTI, and HIV-1 population sequencing was performed in the first plasma sample with an HIV load >500 copies/mL.

Antiretroviral drug concentration assay. Nevirapine and efavirenz plasma drug concentrations were measured by validated high-performance liquid chromatography methods, with a lower limit of quantification of 0.05–0.25 mg/L for nevirapine and 0.05–0.2 mg/L for efavirenz. For this analysis, a threshold value for detection of ≥0.25 mg/L for nevirapine and ≥0.2 mg/L for efavirenz was used. All of the laboratories involved in this study participate in International Quality Control Programs for antiretroviral drug measurements [8, 9].

HIV-1 resistance assay. HIV RNA population sequencing was performed in local PENTA network laboratories. Viral nucleic acid was extracted from plasma with use of Qiagen or Roche systems, and the pol-gene PCR was amplified and se-

**Statistical analysis.** Day 0 was defined as the day on which treatment with the NNRTI was stopped; this was the day of randomization for 12 children (34%) but ranged from 1 to 16 days after randomization for the remaining children because of logistical issues. Baseline characteristics are given for the time of randomization except for laboratory measurements, which are those recorded nearest to (before or on) day 0. For the virologic evaluations after treatment interruption, viral load measurements recorded below a limit of detection of >50 copies/mL (e.g., <400 copies/mL) were assumed to be >50 copies/mL.

**RESULTS**

Of the 110 children enrolled in PENTA-11 between November 2004 and December 2006, 56 were randomized to the PTI arm. Of these children, 35 stopped treatment with an NNRTI-containing HAART regimen: 20 stopped treatment with nevirapine, and 15 stopped treatment with efavirenz (figure 1). Baseline characteristics of children interrupting treatment with an NNRTI are shown in table 1. Of note, at day 0, viral load was ≥50 copies/mL (range, 50–700 copies/mL) in 6 (17%) of the children despite being stable at ≤50 copies/mL for the previous 6 months, up to and including the screening visit. Four of these 6 children followed a staggered stop strategy, and 2 followed a replacement stop strategy.

Of the NNRTI-based regimens that were interrupted, 27 (77%) of 35 included lamivudine. A staggered stop strategy was used for 11 (55%) of the children interrupting treatment with nevirapine; lamivudine was included in 7 of these regimens, and 2 children had lamivudine switched to didanosine for 1 week. All 9 children who stopped treatment with nevirapine using a replacement stop strategy were receiving lamivudine; 6 children had lamivudine replaced with didanosine and had lopinavir-ritonavir added to the regimen, and 3 children retained lamivudine and had either lopinavir-ritonavir (2 children) or nelfinavir (1 child) added to their regimen. Similarly, 10 (67%) of 15 children interrupted treatment with efavirenz using a staggered stop strategy; lamivudine was included in 8 of these regimens, but only 1 child had lamivudine switched to didanosine. Five children interrupted treatment with efavirenz with a replacement stop strategy, and all had lopinavir-ritonavir added to the regimen; lamivudine was included in 3 of these regimens, and lamivudine was switched to didanosine for 1 child.

The median time from stopping treatment with the NNRTI to stopping treatment with all drugs was 9 days (range, 6–15 days) for children receiving nevirapine and 14 days (range, 6–18 days) for children receiving efavirenz. For the staggered stop strategy, the median times were 8 days (range, 6–14 days) and 14 days (range, 6–18 days) for nevirapine and efavirenz, respectively; 14 days (range, 6–15 days) was the median time for a replacement stop strategy for both drugs.

**NNRTI plasma drug concentrations after treatment interruption.** Plasma drug concentration data were available for 19 children stopping treatment with nevirapine and 14 children stopping treatment with efavirenz. The percentages of
Table 1. Baseline demographic and clinical characteristics of children who interrupted treatment with a nevirapine (NVP)– or efavirenz (EFV)–containing HAART regimen.

<table>
<thead>
<tr>
<th>Variable</th>
<th>NVP group (n = 20)</th>
<th>EFV group (n = 15)</th>
<th>All patients (n = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>9 (45)</td>
<td>7 (47)</td>
<td>16 (46)</td>
</tr>
<tr>
<td>Female</td>
<td>11 (55)</td>
<td>8 (53)</td>
<td>19 (54)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>5 (25)</td>
<td>3 (20)</td>
<td>8 (23)</td>
</tr>
<tr>
<td>Black</td>
<td>5 (25)</td>
<td>6 (40)</td>
<td>11 (31)</td>
</tr>
<tr>
<td>Asian</td>
<td>8 (40)</td>
<td>3 (20)</td>
<td>11 (31)</td>
</tr>
<tr>
<td>Mixed</td>
<td>2 (10)</td>
<td>3 (20)</td>
<td>5 (14)</td>
</tr>
<tr>
<td>Age, median years (range)</td>
<td>8.3 (3.6–15.9)</td>
<td>9.4 (5.0–15.0)</td>
<td>8.9 (3.6–15.9)</td>
</tr>
<tr>
<td>HIV RNA level &lt;50 copies/mL</td>
<td>17 (85)</td>
<td>11 (79)</td>
<td>28 (82)</td>
</tr>
<tr>
<td>CD4 cell count, median cells/µL (range)</td>
<td>1033 (531–2100)</td>
<td>919 (487–2646)</td>
<td>1026 (487–2646)</td>
</tr>
<tr>
<td>CD4 cell percentage, median % (range)</td>
<td>38 (29–53)</td>
<td>36 (24–42)</td>
<td>38 (24–53)</td>
</tr>
<tr>
<td>Previous ART exposure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All 3 main classes</td>
<td>5 (25)</td>
<td>5 (33)</td>
<td>10 (29)</td>
</tr>
<tr>
<td>NRTI plus NNRTI</td>
<td>15 (75)</td>
<td>10 (67)</td>
<td>25 (71)</td>
</tr>
<tr>
<td>ART drugs received, median no. (range)</td>
<td>4 (3–8)</td>
<td>4 (3–8)</td>
<td>4 (3–8)</td>
</tr>
<tr>
<td>All 3 main classes</td>
<td>2.5 (2–4)</td>
<td>3 (2–5)</td>
<td>3 (2–5)</td>
</tr>
<tr>
<td>NRTIs</td>
<td>1 (1–2)</td>
<td>1 (1–2)</td>
<td>1 (1–2)</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>0 (0–3)</td>
<td>0 (0–2)</td>
<td>0 (0–3)</td>
</tr>
<tr>
<td>Cumulative ART exposure, median years (range)</td>
<td>5.2 (1.7–15.3)</td>
<td>6.1 (2.7–10.8)</td>
<td>5.4 (1.7–15.3)</td>
</tr>
<tr>
<td>All ART drugs</td>
<td>5.2 (1.7–11.6)</td>
<td>6.1 (2.7–10.8)</td>
<td>5.4 (1.7–11.6)</td>
</tr>
<tr>
<td>NRTIs</td>
<td>4.0 (1.7–7.7)</td>
<td>3.7 (1.9–7.9)</td>
<td>3.7 (1.7–7.9)</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>0 (0–8.5)</td>
<td>0 (0–6.3)</td>
<td>0 (0–8.5)</td>
</tr>
</tbody>
</table>

**NOTE.** Data are no. (%) of patients, unless otherwise indicated. Baseline characteristics are given at the time of randomization except for laboratory measurements, which are those measurements recorded nearest to or on (but not after) the day on which the NNRTI was stopped (day 0). ART, antiretroviral therapy; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.

a Data on HIV RNA level at day 0 was unavailable for 1 child; percentages are for children with available data.

b CD4 cell count and CD4 cell percentage data at day 0 were unavailable for 1 child; percentages are for children with available data.

children with nevirapine and efavirenz plasma concentrations above the threshold at 0, 7, 14, and 28 days after treatment with the NNRTI was stopped are shown in figure 2.

At the time of stopping treatment with nevirapine, the median nevirapine dose was 306 mg/m2 (range, 221–410 mg/m2), and the plasma concentration was 7.0 mg/L (range, 2.2–15.1 mg/L) (3 children had plasma concentrations that were less than the target therapeutic concentration of 3.0 mg/L [14]). Of 19 children, 1 child (whose plasma concentration at day 0 was 15.05 mg/L) had a nevirapine plasma concentration >0.25 mg/L (1.31 mg/L) 7 days after stopping treatment with nevirapine, which decreased to 0.12 mg/L by day 14 (lower limit of quantification [LLOQ] of the assay was 0.05 mg/L; nevirapine concentrations were not measured for this child after day 14). Of the 18 remaining children, 16 had samples assayed with a more sensitive assay, 1 with an LLOQ of 0.15 mg/L, 6 with an LLOQ of 0.10 mg/L, and 9 with an LLOQ of 0.05 mg/L. At 7 days, 5 children had nevirapine plasma concentrations above the LLOQ for the assay but below 0.25 mg/L (0.057, 0.060, 0.060, 0.064, and 0.149 mg/L); of these children, 3 had nevirapine concentrations >10.0 mg/L at day 0. At 14 days, no children had a nevirapine concentration >0.25 mg/L, and only 1 child had a detectable plasma concentration above the LLOQ for the assay (described above).

The median efavirenz dose and median plasma drug concentration at treatment interruption were 12.3 mg/kg (range, 8.1–17.2 mg/kg) and 2.0 mg/L (range, 0.3–3.5 mg/L), respectively, for 12 children, including 2 with plasma concentrations less than the target therapeutic concentration of 1.0 mg/L [14]. Of 8 children, 4 had detectable efavirenz plasma concentrations >0.20 mg/L (0.40, 0.54, 0.61, and 4.07 mg/L) 7 days after stopping treatment (time from stopping treatment with efavirenz to stopping treatment with all drugs was 13, 18, 7, and 6 days, respectively). Among the 4 remaining children, all had samples
assayed with a more sensitive assay (3 with an LLOQ of 0.05 mg/L and 1 with an LLOQ of 0.078 mg/L); 2 of these children had efavirenz plasma concentrations above the LLOQ for the assay but <0.20 mg/L at day 7 after stopping treatment (0.12 and 0.19 mg/L). The 2 children with the greatest efavirenz plasma concentrations >0.20 mg/L at day 7 also had plasma concentrations of 0.26 and 0.32 mg/L 14 days after interruption. One additional child, for whom plasma concentrations were not measured at day 7, had an efavirenz plasma concentration of 0.29 mg/L 14 days after stopping efavirenz (time from stopping efavirenz to stopping all drugs was 6 days). Two of the 3 children with detectable concentrations at day 14 were also tested at day 28, and no efavirenz was detected.

Viral load rebound. At day 14, 6 (38%) of 16 and 2 (17%) of 12 children interrupting treatment with nevirapine and efavirenz, respectively, had viral loads >50 copies/mL (range for the nevirapine group, 52–7000 copies/mL; range for the efavirenz group, 120–1600 copies/mL), which increased to 19 (95%) of 20 and 12 (92%) of 13 by day 28 (range for the nevirapine group, 300–4,897,788 copies/mL; range for the efavirenz group, <100 to 147,000 copies/mL) (table 2).

NNRTI resistance. HIV genotyping was performed at various times during the first 3 months after interruption of treatment with an NNRTI, depending on viral load values (for 1 child at week 2, 21 children at week 4, 10 children at week 8, and 2 children at week 12). For 1 child, cDNA could not be amplified. No new NNRTI resistance mutations were detected in virus from the 35 children interrupting treatment with an NNRTI-containing HAART regimen. One child who was receiving nevirapine had the NNRTI resistance mutation K103N detected 14 days after stopping treatment with nevirapine, but this child had a viral load of 700 copies/mL at day 0 (<50 copies/mL at the screening visit), and the K103N resistance mutation could also be detected in virus isolated from a stored sample taken at day 0. No lamivudine-associated resistance mutations were detected in virus obtained from any of the children.

DISCUSSION

In this substudy of virologically suppressed HIV-infected children enrolled in PENTA-11 trial and undergoing a PTI, we found that nevirapine and efavirenz plasma drug concentrations were below the detection threshold in the majority of children at 1 week (for those stopping treatment with nevirapine) and 2 weeks (for those stopping treatment with efavirenz) after treatment interruption and were below the lower limit of detection for all children at 2 weeks (for those stopping treatment with nevirapine) and 4 weeks (for those stopping treatment with efavirenz). No new NNRTI or lamivudine resistance mutations were detected.

We observed that efavirenz persisted longer than nevirapine in plasma. This result was apparent early in the trial, and we changed the management strategy to recommend staggered stop or replacement stop of efavirenz for 14 days rather than 7 days. At this time, a 7–14-day staggered stop strategy was recommended for children stopping treatment with nevirapine. The final analysis confirmed that efavirenz had longer persistence, an observation that was consistent with reports involving adults. For example, in a report describing 8 adults who interrupted treatment with efavirenz, median plasma concentrations were 0.31, 0.15, and 0.06 mg/L at 7, 14, and 21 days, respectively [3]. In a substudy of the Development of Antiretroviral Therapy in Africa (DART) trial, in which adults interrupted treatment with nevirapine using a 1-week staggered stop strategy, 5 (28%) of 18 patients had nevirapine concentrations >0.2 mg/L at 7 days, decreasing to only 1 (5%) of 19 patients by day 14 [4].

In our study, a staggered stop or replacement stop of 6–18 days (median duration, 14 days) was used for children interrupting treatment with efavirenz, and no new NNRTI resistance selection was observed as viral load increased. Despite this, the high percentage of children with efavirenz concentrations >0.20 mg/L at 14 days, coupled with the persistence of efavirenz for 3 weeks [3] and sometimes longer in adults [12], would suggest that a staggered stop or replacement stop duration >14 days should be advocated. The authors of the DART substudy suggest that a 7–10-day staggered stop strategy is adequate for African patients discontinuing treatment with nevirapine, for whom protease inhibitor replacement is not feasible. In our study, a staggered stop or replacement stop of 6–15 days (median duration, 9 days) was used for children interrupting treatment with nevirapine, and no NNRTI resistance was found. Of interest, whereas median nevirapine concentrations at treatment interruption were similar in our study and the DART...
Table 2. Proportion (%) of children with HIV RNA load $\geq$50 copies/mL at 0, 14, and 28 days after interrupting a nevirapine- or efavirenz-containing HAART regimen with use of either a staggered stop (SS) or replacement stop (RS) strategy.

<table>
<thead>
<tr>
<th>Treatment interruption strategy</th>
<th>Nevirapine group</th>
<th>Efavirenz group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 0</td>
<td>Day 14</td>
</tr>
<tr>
<td>SS and RS</td>
<td>3/20 (15)</td>
<td>6/16 (38)</td>
</tr>
<tr>
<td>SS</td>
<td>2/11 (18)</td>
<td>3/9 (33)</td>
</tr>
<tr>
<td>RS</td>
<td>1/9 (11)</td>
<td>3/7 (43)</td>
</tr>
</tbody>
</table>

In conclusion, in virologically suppressed children who interrupt an NNRTI-based HAART regimen during the first PTI cycle, the adoption in this trial of a staggered stop or replacement stop strategy for a median duration of 9 days for nevirapine and 14 days for efavirenz was not associated with the selection of drug resistance mutations. Whether a replacement stop or staggered stop is preferable could not be determined, although there are theoretical reasons to prefer a replacement stop strategy, particularly for efavirenz, which...
persists longer than nevirapine. However, our data are consistent with other studies in which a staggered stop strategy for nevirapine appeared to be adequate. We are continuing to monitor HIV load, drug resistance, and drug concentrations in children who undergo subsequent PTIs.

**MEMBERS OF PENTA**


PENTA-11 Data Safety and Monitoring Committee: C. Hill (Chair), P. Lepage, A. Pozniak, and S. Vella.


Medical University of Warsaw/Regional Hospital of Infectious Diseases, Warsaw, Poland: M. Marczynska, S. Dobosz, A. Oldakowska, J. Popielska, M. Kaflik, J. Stanczak, T. Stanczcz, and T. Dyda.


University Childen’s Hospital, Switzerland: C. Kalhert and D. Nadal. National Laboratory for Retrovirus, Zurich, Switzerland: J. Schupbach.


**Pharmacology laboratories.** Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands: D. M. Burger.

Acknowledgments

We thank all of the children, families, and staff from the centers participating in the PENTA-11 Treatment Interruption in Children with Chronic HIV-Infec­tion Trial. In the PENTA-11 trial, children were enrolled from 9 countries: France (10 children), Germany (4), Italy (19), Poland (3), Spain (17), Switzerland (2), Thailand (23), the United Kingdom (28), and the United States (4).

Financial support. PENTA is a coordinated action of the European Commission, supported by the Sixth Framework contract LSHP-CT-2006-018865 and Fifth Framework Program contractQLK2-2000-00150. The PENTA-11 trial is sponsored by the PENTA Foundation in Europe and Thailand and by National Institute of Child Health and Human Development in the United States. The trial is coordinated by 4 trial centers: the Medical Research Council Clinical Trials Unit, London, United Kingdom (with support from the MRC), INSERM SC10, Paris, France (supported by Agence Nationale de Recherche sur le SIDA), Program for HIV Prevention and Treatment, Chiang Mai, Thailand (with support from the PENTA Foundation and Institut de Recherche pour le Développement—URI 174), and Westat, Maryland (supported by National Institute of Child Health and Human Development). Collaborating centers in the United Kingdom are supported by a grant from the MRC; those in Italy are supported by a grant from the Istituto Superiore di Sanità-Progetto Terapia Antiretrovirale 2002-2005. PENTA activities are also supported by the PENTA Foundation.

Potential conflicts of interest. The University of Liverpool HIV therapeutic drug monitoring service was developed into Delphic Diagnostics in 2005, and S.K. serves as nonexecutive director of Delphic Diagnostics. S.K. has also received research awards from Boehringer as part of 2 inter­national therapeutic drug monitoring trials of tipranavir (Spring and Ti­cino). All other authors: no conflicts.

References